Clinical Trial Update: Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia/ Lymphoblastic Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1 and Phase 2 trial update for ruxolitinib and chidamide in acute T cell lymphoblast leukemia/lymphoblastic lymphoma ongoing; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cell Lymphoblast Leukemia
• Lymphoblastic Lymphoma

Drugs mentioned

• Chidamide (chidamide)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Peripheral Blood Stem Cell Transplantation | Phase 1, Phase 2 | Status: UNKNOWN